Literature DB >> 10389759

Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines.

J G Asschert1, E Vellenga, M H Ruiters, E G de Vries.   

Abstract

Autocrine and paracrine production of interleukin-6 (IL-6) is considered to be involved in the ongoing proliferation of ovarian-cancer cells. In view of the variability in IL-6 expression between various ovarian-cancer cells, we questioned whether differences in IL-6-gene regulation might be observed in ovarian tumor cells with and without IL-6 expression. The CAOV-3 cell line spontaneously secreted IL-6, which was enhanced by tumor necrosis factor-alpha (877 +/- 89 vs. 8,452 +/- 1,762 pg/ml, x +/- sd, p < 0.01). The electrophoretic mobility shift assay (EMSA) demonstrated that basic IL-6 expression was associated with DNA binding of activator protein-1 (AP-1) and nuclear factor IL-6 (NF-IL6). Nuclear factor kappa-B (NF-KB), which consisted mainly of p65-NF-KB was induced in response to TNF-alpha stimulation. A2780 cells did not express IL-6, either spontaneously or after stimulation with TNF-alpha. EMSAs, showed spontaneous AP-1 but no NF-IL6 or NF-KB DNA binding. TNF-alpha stimulation enhanced AP-1 and induced NF-KB but no NF-IL6 DNA binding in these cells. NF-IL6 protein, however, was detected in nuclear extracts of these cells by Western blotting. In contrast, IL-6-promoter transfection studies showed no difference in promoter activation between CAOV-3 and A2780. This study reveals that differential IL-6-gene expression observed in ovarian-cancer cell lines is independent of NF-IL6 activation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389759     DOI: 10.1002/(sici)1097-0215(19990719)82:2<244::aid-ijc15>3.0.co;2-n

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Targeted ovarian cancer treatment: the TRAILs of resistance.

Authors:  Nadzeya Goncharenko Khaider; Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

2.  IL-6 -174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls.

Authors:  Bin Xu; Xiao-Bing Niu; Zi-Dun Wang; Wei Cheng; Na Tong; Yuan-Yuan Mi; Zhi-Chao Min; Jun Tao; Peng-Chao Li; Wei Zhang; Hong-Fei Wu; Zheng-Dong Zhang; Zeng-Jun Wang; Li-Xin Hua; Ning-Han Feng; Xin-Ru Wang
Journal:  Mol Biol Rep       Date:  2010-11-23       Impact factor: 2.316

3.  Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells.

Authors:  Takeharu Kanazawa; Hiroshi Nishino; Masahiro Hasegawa; Yasushi Ohta; Yukiko Iino; Keiichi Ichimura; Yutaka Noda
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-02-20       Impact factor: 2.503

4.  Normal and SV40 transfected human peritoneal mesothelial cells produce IL-6 and IL-8: implication for gynaecological disease.

Authors:  X Y Zhang; M Guckian; N Nasiri; P A Lovell; A G Dalgleish; D P J Barton
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

5.  γ-Tocotrienol inhibits lipopolysaccharide-induced interlukin-6 and granulocyte colony-stimulating factor by suppressing C/EBPβ and NF-κB in macrophages.

Authors:  Yun Wang; Qing Jiang
Journal:  J Nutr Biochem       Date:  2012-12-15       Impact factor: 6.048

6.  Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats.

Authors:  Allison C Sharrow; Brigitte M Ronnett; Christopher J Thoburn; James P Barber; Robert L Giuntoli; Deborah K Armstrong; Richard J Jones; Allan D Hess
Journal:  J Ovarian Res       Date:  2010-03-31       Impact factor: 4.234

7.  Effect of IL-6 and IL-8 on the expression of the complement activation inhibitors MAC-inhibitory protein and decay-accelerating factor in ovarian cancer A2780 cells.

Authors:  Lucyna Kapka-Skrzypczak; Sylwia Popek; Krzysztof Sawicki; Ewa Wolińska; Magdalena Czajka; Maciej Skrzypczak
Journal:  Oncol Lett       Date:  2016-06-28       Impact factor: 2.967

8.  Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: an experimental study with nu/nu athymic mice.

Authors:  Qiong-yan Lin; Yi-feng Wang; Hui-nan Weng; Xiu-jie Sheng; Qing-ping Jiang; Zhi-ying Yang
Journal:  J Zhejiang Univ Sci B       Date:  2012-11       Impact factor: 3.066

9.  Regulation of gene expression in ovarian cancer cells by luteinizing hormone receptor expression and activation.

Authors:  Juan Cui; Brooke M Miner; Joanna B Eldredge; Susanne W Warrenfeltz; Phuongan Dam; Ying Xu; David Puett
Journal:  BMC Cancer       Date:  2011-06-28       Impact factor: 4.430

10.  Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients.

Authors:  Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  BMC Cancer       Date:  2011-05-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.